Extended-Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder.
- Published in:
- CNS Drugs, 2023, v. 37, n. 7, p. 655, doi. 10.1007/s40263-023-01023-6
- By:
- Publication type:
- Article
Works matching IS 11727047 AND DT 2023 AND VI 37 AND IP 7
Results: 7
1
2
Increased Metabolic Potential, Efficacy, and Safety of Emerging Treatments in Schizophrenia.
- Published in:
- CNS Drugs, 2023, v. 37, n. 7, p. 545, doi. 10.1007/s40263-023-01022-7
- By:
- Publication type:
- Article
3
Number, Duration, and Distribution of Wake Bouts in Patients with Insomnia Disorder: Effect of Daridorexant and Zolpidem.
- Published in:
- CNS Drugs, 2023, v. 37, n. 7, p. 639, doi. 10.1007/s40263-023-01020-9
- By:
- Publication type:
- Article
4
Correction to: Rimegepant: A Review in the Acute Treatment and Preventive Treatment of Migraine.
- Published in:
- CNS Drugs, 2023, v. 37, n. 7, p. 661, doi. 10.1007/s40263-023-01019-2
- By:
- Publication type:
- Article
5
Turning the Spotlight to Cholinergic Pharmacotherapy of the Human Language System.
- Published in:
- CNS Drugs, 2023, v. 37, n. 7, p. 599, doi. 10.1007/s40263-023-01017-4
- By:
- Publication type:
- Article
6
BRAF Mutations in CNS Tumors—Prognostic Markers and Therapeutic Targets.
- Published in:
- CNS Drugs, 2023, v. 37, n. 7, p. 587, doi. 10.1007/s40263-023-01016-5
- By:
- Publication type:
- Article
7
The Serotonin 1A (5-HT<sub>1A</sub>) Receptor as a Pharmacological Target in Depression.
- Published in:
- CNS Drugs, 2023, v. 37, n. 7, p. 571, doi. 10.1007/s40263-023-01014-7
- By:
- Publication type:
- Article